Cardiovascular Drugs and Therapy

, Volume 3, Issue 5, pp 767–770 | Cite as

Effects of pindolol and propranolol on blood lipids in hypertensive patients

  • Oscar Román
  • M. Eugenia Pino
  • Tamara Pereda
  • Angélica Valenzuela


Since beta-blockers could affect lipid levels at the therapeutic dose range in hypertensive patients, a parallel 6-month randomized trial with pindolol (PDL) (16 pts.) and propranolol (PPL) (23 pts.) was designed (mean age=55+7.1 years and 57+8.0 years; 9 males, 7 females and 15 males, 8 females, respectively). Total cholesterol, LDL and HDL fractions, and triglycerides (TGs) were determined before (washout phase) and during 1, 3, and 6 months of therapy. Patients were instructed to maintain their usual dietary habits. Daily drug doses were adjusted step by step to attain an optimal hypotensive effect (PDL 15–45 mg, PPL 180–240 mg). In the PPL-treated group, total cholesterol and LDL did not change significantly, HDL decreased (from 45.2 to 40.5 mg/dl, p<0.05) and TG increased (from 133 to 169 mg/dl, p<0.05). In the PDL group total cholesterol and LDL did not change either, but HDL increased (35.9 to 44.7 mg/dl, p<0.01) and TGs, were reduced (from 169 to 131 mg/dl, p<0.05). No dose-effect relationship was recorded. It is concluded that pindolol does not negatively influence HDL nor the TG blood lipid profile as does PPL. Accordingly, pindolol might be preferred to propranolol in the treatment of hypertensive patients with an unfavorable lipid profile, but this assumption remains to be proven in larger, prospective, long-term followup trials.

Key Words

pindolol propranolol beta blockers hypertension blood lipids 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Veterans Administration Cooperative Study Group on Antihypertensive agents. Effects of treatment on morbidity in hypertension.JAMA 1970; 213:1143–1152.Google Scholar
  2. 2.
    Report by the Management Committee. The Australian therapeutic trial on mild hypertension.Lancet 1980; 1:1261–1267.Google Scholar
  3. 3.
    Amery A, Birkenhager W, Brixho P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial.Lancet 1985; 1:1349–1354.PubMedGoogle Scholar
  4. 4.
    Helgeland A, Hjermann I, Holme I, Leren P. Serum triglycerides and serum uric acid in untreated and thiazide treated patients with mild hypertension. The Oslo study.Am J Med 1978; 64:34–38.PubMedGoogle Scholar
  5. 5.
    Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial. Risk factor changes and mortality results.JAMA 1982; 248:1465–1477.Google Scholar
  6. 6.
    Weinberger MH. Antihypertensive therapy and lipids. Evidence, mechanisms and implications.Arch Intern Med 1985; 145:1102–1105.PubMedGoogle Scholar
  7. 7.
    Beevers DG, Hamilton M, Harpur JE. Long term treatment of arterial hypertension with thiazide diuretics.Post Grad Med J 1971; 47:639.Google Scholar
  8. 8.
    Ames RP, Hill P. Elevation of serum lipids levels during diuretic therapy of hypertension.Am J Med 1976; 61:748–757.PubMedGoogle Scholar
  9. 9.
    Goldman AL, Steele BW, Schapes HW, et al. Serum lipoprotein levels during chlortalidone therapy.JAMA 1980;244:1961–1965.Google Scholar
  10. 10.
    Román O, Pino ME, Valenzuela A. Effects of pindolol and clopamide on blood lipids in arterial hypertensive patients.Cardiology 1987; 74:219–225.PubMedGoogle Scholar
  11. 11.
    Leren P, Fors OP, Helgeland A, et al. Effects of pindolol and hydrochlorothiazide on blood lipids. The Oslo Study.Clin Trials J 1981; 18:254–261.Google Scholar
  12. 12.
    Lehtonen A. Effect of beta blockers on blood lipid profile.Am Heart J 1985; 109:1192–1197.PubMedGoogle Scholar
  13. 13.
    Greenberg G, Brennan PJ, Miall NE. Effects of diuretic and beta-blocker therapy in the Medical Research Council trial.Am J Med 1984; 76:45–51.PubMedGoogle Scholar
  14. 14.
    Lasser NL, Grandeta, Cagguila AW, et al. Effects of antihypertensive therapy on plasma lipids and lipoproteins in the Multiple Risk Factor Intervention trial.Am J Med 1984; 76(2A):52–66.Google Scholar
  15. 15.
    Pasotti C, Capra A, Fiorella G, et al. Effects of pindolol and metoprolol on plasma lipids and lipoproteins.Br J Clin Pharmacol 1982; 13:4355–4395.Google Scholar
  16. 16.
    Lehtonen P. A long term effect of pindolol on plasma lipids, apoprotein A, blood glucose and serum-insulin levels.Int J Clin Pharm Ther Tox 1984; 22:269.Google Scholar
  17. 17.
    Tanuka N, Sakaguchi S, Oshige K, et al. Effect of chronic administration of propranolol on lipoprotein composition.Metabolism 1976; 25:1071–1076.PubMedGoogle Scholar
  18. 18.
    Lehtonen A, Hietanen E, Marniemi J, et al. Effect of Pindolol on serum lipids and lipid metabolizing enzymes.Br J Pharmacol 1982; 13:4455–4485.Google Scholar
  19. 19.
    Allain CL, Poon LS, et al. Enzymatic determination of total serum cholesterol.Clin Chem 1974; 20:470–475.PubMedGoogle Scholar
  20. 20.
    Tiffany TO, Morton JM, Hall EM, Garrett AS. Clinical evaluation of kinetic enzymatic fixed time and integral analysis of serum triglycerides.Clin Chem 1974; 20:427.Google Scholar
  21. 21.
    López MF, Stone P, Ellis S, Colwell JA. Cholesterol determination in high density lipoproteins separated by three different methods.Clin Chem 1977; 23:882–884.PubMedGoogle Scholar
  22. 22.
    Shaw J, England JDF, Hua ASP. Beta blockers and plasma triglycerides.Br Med J 1987; 1:986.Google Scholar
  23. 23.
    Leren P, Helgeland A, Holme I, et al. Effect of propranolol and prazosin on blood lipid. The Oslo study.Lancet 1980; 2:4.PubMedGoogle Scholar
  24. 24.
    Northcote RJ, Ballantyne D. The influence of intrinsic sympathomimetic activity on the lipoprotein profile during beta-adrenoceptor blockade.Clin Sci 1985; (Suppl 12):57P.Google Scholar
  25. 25.
    Day JL, Metcalfe J, Simpson CN. Adrenergic mechanisms in control of plasma lipid concentrations.Br Med J Res 1982; 284:1145–1148.Google Scholar
  26. 26.
    England JDF, Simons LA, Gibson JC, et al. The effect of metoprolol and atenolol on plasma high density lipoprotein levels in man.Clin Exp Pharmacol Physiol 1980; 7:329–333.PubMedGoogle Scholar
  27. 27.
    Fain JN. Biochemical aspects of drug and hormone action on adipose tissue.Pharmac Rev 1973; 25:67–79.Google Scholar
  28. 28.
    Mc Congle RJS, Williams L, Murphy MJ, et al. Labetalol and lipids.Lancet 1981; 1:163.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1989

Authors and Affiliations

  • Oscar Román
    • 1
  • M. Eugenia Pino
    • 1
  • Tamara Pereda
    • 1
  • Angélica Valenzuela
    • 1
  1. 1.Paula Jaraquemada HospitalSantiagoChile

Personalised recommendations